Clinical Takeaway
CBD can interact with other medications, particularly opioids and drugs processed by the same liver enzymes, which matters most for cancer patients already taking multiple medications. Patients and clinicians should be aware that adding CBD to an existing medication regimen requires careful monitoring, especially in complex cases involving polypharmacy.
#20 Drug Interactions in People on Cannabidiol: Is There Cause for Concern?
Citation: Downs Georgia et al.. Drug Interactions in People on Cannabidiol: Is There Cause for Concern?. Cannabis and cannabinoid research. 2026. PMID: 39539239.
Design: 5 Journal: 1 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Abstract: INTRODUCTION: Cannabidiol (CBD) exhibits multiple therapeutic properties, but its use in advanced cancer patients raises concerns about potential drug-drug interactions (DDIs) due to polypharmacy. This study aims to look for evidence of DDIs between concomitant medications and CBD oil in a randomized placebo-controlled trial of CBD oil for symptom control (MedCan-1 parent study). MATERIALS AND METHODS: Surrogate measures were used to identify possible drug interactions: (1) the maximum mL of oil self-selected by patients in CBD or placebo groups in relation to opioids, specific drug groups, or individual agents; (2) the occurrence of any new or worse adverse effect in relation to the study arm and the concomitant medication classes/medications of interest. RESULTS: The dose of CBD self-selected by participants was not related to opioid use or medications, including benzodiazepines and antipsychotics. The likelihood of developing an adverse effect while on study or when taking specific medications was not increased by CBD. Participants on paracetamol tolerated a higher dose of CBD. DISCUSSION: Concerns regarding the development of clinically significant drug interactions when taking CBD in the context of anti-cancer and other concomitant medications at least in the short term may be unfounded.
What This Study Teaches Us
In advanced cancer patients taking multiple medications, CBD oil did not trigger dose-limiting interactions with opioids, benzodiazepines, antipsychotics, or other common agents. Patients self-selected their CBD doses without apparent constraint from concurrent drug use, and adverse event rates were not increased by CBD compared to placebo.
Why This Matters Clinically
Clinicians often hesitate to recommend CBD to polypharmacy patients, particularly those on opioids or CNS-active drugs, due to theoretical interaction concerns. This trial offers reassurance that short-term CBD use in oncology patients does not appear to create clinically significant interactions with standard cancer supportive care medications, which may help inform shared decision-making.
Study Snapshot
| Study Design | Randomized placebo-controlled trial (MedCan-1 parent study) |
| Population | Advanced cancer patients on polypharmacy; exact N and demographics not specified in abstract |
| Intervention | CBD oil (dose self-selected by participants) versus placebo; duration not specified in abstract |
| Primary Outcome | Surrogate markers of drug-drug interactions: self-selected CBD dose in relation to concomitant medications and adverse event occurrence |
| Key Result | CBD dose was not limited by opioid, benzodiazepine, or antipsychotic use; adverse events were not increased with CBD; patients on paracetamol tolerated higher CBD doses |
Where This Paper Deserves Skepticism
The abstract does not report the actual sample size, the duration of follow-up, or specific CBD dosing ranges achieved, all of which limit interpretation of the magnitude of this finding. Using surrogate markers (dose tolerance and adverse event incidence) rather than direct pharmacokinetic or pharmacodynamic measures leaves open the question of whether subclinical interactions occurred undetected. The study is also limited to cancer patients in the short term, so generalizability to other populations or longer-term use remains unclear.
Dr. Caplan’s Take
I find this study practically useful but appropriately cautious. The fact that patients in an oncology setting did not self-limit their CBD doses around high-risk medications like opioids and benzodiazepines, and that adverse events did not cluster in the CBD arm, suggests we may have been overcautious. That said, this is surrogate data from a specific population over an unspecified timeframe. I would not take this as license to ignore CBD-drug interactions altogether, but it does shift my clinical stance from presumed concern toward measured reassurance, especially in cancer patients where symptom burden and polypharmacy are the rule.
Clinical Bottom Line
In advanced cancer patients on multiple medications, CBD oil appears safe in the short term without dose-limiting interactions with opioids or other common agents, though this is based on surrogate markers rather than pharmacokinetic evidence. Clinicians can discuss CBD as an option without assuming automatic interaction risk, while remaining alert to individual patient factors and longer-term use patterns.
|
Have thoughts on this? Share it:
